Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126643791 | 12664379 | 1 | I | 20160811 | 20160818 | 20160818 | EXP | US-ASTRAZENECA-2016SE87538 | ASTRAZENECA | 0.00 | M | Y | 0.00000 | 20160818 | OT | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126643791 | 12664379 | 1 | PS | SEROQUEL | QUETIAPINE FUMARATE | 1 | Oral | U | 20639 | TABLET | |||||||||
126643791 | 12664379 | 2 | SS | ABILIFY | ARIPIPRAZOLE | 1 | Unknown | 0 | |||||||||||
126643791 | 12664379 | 3 | SS | ABILIFY | ARIPIPRAZOLE | 1 | Unknown | 0 | |||||||||||
126643791 | 12664379 | 4 | C | LITHIUM. | LITHIUM | 1 | 0 | ||||||||||||
126643791 | 12664379 | 5 | C | DEPAKOTE | DIVALPROEX SODIUM | 1 | 0 | ||||||||||||
126643791 | 12664379 | 6 | C | SAPHRIS | ASENAPINE MALEATE | 1 | 0 |
Indications of drugs used
no results found |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126643791 | 12664379 | HO |
126643791 | 12664379 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126643791 | 12664379 | Anger | |
126643791 | 12664379 | Patient uncooperative | |
126643791 | 12664379 | Psychotic disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126643791 | 12664379 | 3 | 20160527 | 0 |